ESMO 2022 Conference Coverage

 

ESMO 2022 Conference Coverage
M

ESMO 2022 Final Analysis of the Randomized, Phase 3 RATIONALE-301 Study: Tislelizumab vs. Sorafenib as 1L Treatment for Unresectable HCC

By ESMO 2022 Conference Coverage FEATURING Masatoshi Kudo
By ESMO 2022 Conference Coverage FEATURING Masatoshi Kudo
94 views
September 19, 2022
0 Comments
Login to view comments. Click here to Login
GI
07:10
ESMO 2022 Conference Coverage

ESMO 2022 on ctDNA Dynamics, CEA, and Sites of Recurrence for the Ra…

Feat. J. Tie
01:21
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on Characterizing the Clinico-Genomic La…

Feat. F. Keane
05:27
ESMO 2022 Conference Coverage

ESMO 2022 on Characterizing the Clinico-Genomic Landscape and Outcom…

Feat. F. Keane
01:01
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the NuTide:302 Study: NUC-3373, a Pro…

Feat. A. Coveler
04:14
ESMO 2022 Conference Coverage

ESMO 2022 on the NuTide:302 Study: NUC-3373, a ProTide Transformatio…

Feat. A. Coveler
09:14
ESMO 2022 Conference Coverage

ESMO 2022 on the Global Phase 3 Multiregional Clinical Trial FRESCO-…

Feat. A. Dasari
06:14
ESMO 2022 Conference Coverage

ESMO 2022 on the Phase 3 HIMALAYA Study: Impact of Viral Aetiology o…

Feat. S. L. Chan
12:50
ESMO 2022 Conference Coverage

ESMO 2022 on KRYSTAL-1: Updated Efficacy & Safety of Adagrasib W…

Feat. S. Klempner
43
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Global Phase 3 Multiregional Clin…

Feat. A. Dasari
42
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Updated Analysis of DESTINY-Gastr…

Feat. G. Ku
05:29
ESMO 2022 Conference Coverage

ESMO 2022 Updated Analysis of DESTINY-Gastric02 Trial: T-DXd in West…

Feat. G. Ku
01:26
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Ce…

Feat. A. Orlandi
12:14
ESMO 2022 Conference Coverage

ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Cetuximab vs. FOLFIR…

Feat. A. Orlandi
03:47
ESMO 2022 Conference Coverage

ESMO 2022: Early Decreases in KRAS Mutant Allele Frequency Predicts …

Feat. H. Lenz
01:35
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022: Beyond 1L for mCRC - Best Practices and…

Feat. T. Price
20:07
Timothy Price

Beyond 1L for mCRC - Best Practices and Practical Nuances

16:12
ESMO 2022 Conference Coverage

ESMO 2022 on Advances in HER2-Targeted Therapy or Novel Targeted The…

Feat. K. Shitara
18
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022: Real-World Monitoring of ctDNA Reliably…

Feat. S. Cohen
05:42
ESMO 2022 Conference Coverage

ESMO 2022: Real-World Monitoring of ctDNA Reliably Predicts Cancer R…

Feat. S. Cohen
09:24
ESMO 2022 Conference Coverage

ESMO 2022 Final Analysis of the Randomized, Phase 3 RATIONALE-301 St…

Feat. M. Kudo
04:44
ESMO 2022 Conference Coverage

ESMO 2022 on the Updated OS From the Phase 3 TOPAZ-1 Study: Durvalum…

Feat. D. Oh
46
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: …

Feat. J. Edeline
04:28
ESMO 2022 Conference Coverage

ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: Pembrolizumab vs. …

Feat. J. Edeline
13:16
ESMO 2022 Conference Coverage

ESMO 2022 on the NICHE-2 Study: Neoadjuvant Immune Checkpoint Inhibi…

Feat. M. Chalabi
19
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the HIPECT4 Randomized Phase 3 Study:…

Feat. A. Arjona-Sanchez
05:02
ESMO 2022 Conference Coverage

ESMO 2022 on the HIPECT4 Randomized Phase 3 Study: Adjuvant Hyperthe…

Feat. A. Arjona-Sanchez
22
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase…

Feat. J. Taieb
06:19
ESMO 2022 Conference Coverage

ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Aveluma…

Feat. J. Taieb